SHANGHAI, June 26

上海，6月26日

th

th

, 2025 – LaNova Medicines Ltd. announced CDE has granted LM-108 (anti-CCR8 mAb) Breakthrough Therapy Designation. This designation is for the treatment of patients with CCR8-positive gastric or gastroesophageal junction adenocarcinoma who have disease progression following first-line standard of care treatment..

2025年 - LaNova Medicines Ltd. 宣布中国国家药品监督管理局药品审评中心（CDE）已授予LM-108（抗CCR8单克隆抗体）突破性疗法认定。该认定适用于一线标准治疗后疾病进展的CCR8阳性胃或胃食管交界处腺癌患者的治疗。